Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Peginterferon European Indication Restricted To Rebetron Failures

Executive Summary

Schering-Plough's peginterferon alfa-2b should be used as monotherapy in hepatitis C patients who have failed or are intolerant to ribavirin in interferon-alfa/ribavirin combination therapy (Rebetron), the European Committee for Proprietary Medicinal Products recommends.

You may also be interested in...



Risperdal Depot Formulation May Aid Compliance Among Schizophrenics

Janssen and Alkermes are collaborating to develop a depot formulation of the antipsychotic Risperdal that would be delivered via injection once every two weeks. Risperdal is currently available in daily tablet or oral solution formulations.

Roche Pegasys Once-Weekly Peginterferon Filing Is Set For Early 2000

Roche expects to file a BLA for its pegylated interferon alpha product Pegasys for hepatitis C in 2000, Roche Clinical Science-Virology Director Joseph Hoffman, MD, reported at a Roche R&D meeting in Basel June 14-15.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel